Post-Market Surveillance for Medical Devices: EU, UK, FDA, and Canada Explained

This video is for medical device, IVD, quality, and regulatory professionals who need to strengthen post-market surveillance without creating disconnected processes. It explains what regulators expect, where PMS systems commonly fail, and how to build a more proactive, globally aligned approach across the EU, UK, US, and Canada. Post-market surveillance is no longer a narrow regulatory activity or an annual reporting exercise. In this session, NSF’s Diana Al Tahli outlines how PMS should function as a continuous, proactive, and fully integrated part of the quality management system for medical devices and IVDs. The discussion covers the regulatory intent behind PMS under the EU MDR and IVDR, and shows how real-world data should feed risk management, clinical evaluation, CAPA, labeling, and product improvement across the full device lifecycle. The session explains the difference between PMS plans, PMS reports, and PSURs, and why regulators expect these documents to be current, connected, and actionable rather than static compliance artifacts. It also clarifies how authorities and notified bodies assess PMS effectiveness, including document control, continuity of surveillance activities, proactive data collection, trend reporting, internal traceability, and linkage into the broader QMS. A key focus of the video is global regulatory comparison. Viewers will hear how the EU emphasizes structured PMS documentation, how the UK MHRA expects UK-specific formats and continuous surveillance grounded in real-world evidence, how the FDA evaluates PMS primarily through vigilance, recalls, post-approval commitments, and QMS integration, and how Health Canada focuses on mandatory problem reporting, annual summary reporting, trend analysis, and recall effectiveness. This makes the session highly relevant for pharma, biotech, medical devices, IVD, regulatory strategy, commercialization, clinical operations, manufacturing, patient safety, GxP, validation, governance, training, data integrity, digital transformation, and supply chain stakeholders working in regulated environments. The video also addresses the structural reasons PMS systems break down in practice. Common gaps include weak data collection methods, undefined KPIs and thresholds, incomplete PMS plans, poor integration with ISO 14971 risk management, insufficient linkage to clinical evaluation and PMCF, limited proactive surveillance, weak statistical analysis and trend detection, fragmented cross-functional execution, and poor alignment across regions. These are the kinds of issues that often lead to audit findings, inspection risk, and compliance inefficiencies. Importantly, the session moves beyond problem identification and into execution. It outlines practical strategies to strengthen PMS planning and delivery, including developing comprehensive PMS plans, improving proactive data collection, standardizing field data methods, using digital tools and dashboards for analysis, integrating PMS with CAPA and design controls, clarifying governance and ownership, improving training, and building globally harmonized processes with room for local regulatory requirements. For organizations exploring AI and digital transformation in quality systems, the session also points to the value of automation, centralized systems, and faster signal detection in modern PMS operations. If your team is responsible for medical device or IVD compliance, post-market strategy, complaint handling, vigilance, lifecycle management, or global quality systems, this session provides a clear and practical framework for building a stronger PMS capability that supports both compliance and product performance. We looked at the following issues: How should medical device manufacturers structure post-market surveillance under the MDR and IVDR? What do the EU, UK, FDA, and Health Canada each expect from an effective PMS system? Why do PMS systems fail during audits, inspections, and notified body review? How should PMS connect to risk management, clinical evaluation, CAPA, and design controls? What practical steps can regulated companies take to improve global PMS execution and governance? Suggested Video Chapters 00:00 Introduction and speaker overview 01:45 What PMS means under MDR and IVDR 05:10 Reactive and proactive PMS data sources 09:00 How PMS supports risk management, CER, CAPA, and labeling 13:00 PMS plan, PMS report, and PSUR requirements 18:10 How EU authorities and notified bodies assess PMS effectiveness 23:20 UK MHRA expectations for PMS and real-world evidence 27:30 FDA approach to post-market surveillance and vigilance 31:40 Health Canada PMS expectations and annual summary reporting 35:00 Key regional differences across EU, UK, US, and Canada 38:10 Common structural gaps that lead to nonconformities 42:20 Practical strategies to strengthen PMS planning and execution 46:10 Final takeaways and how NSF supports manufacturers